Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

Cardiovascular risk management by blocking the endocannabinoid system

Tools
- Tools
+ Tools

UNSPECIFIED. (2006) Cardiovascular risk management by blocking the endocannabinoid system. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 114 (2). pp. 75-81. ISSN 0947-7349

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1055/s-2006-923885

Abstract

The specific blockade of endocannabinoids at the level of the cannabinoid receptor 1 (CB1 receptor) is a new therapeutic option to reduce body weight and manage cardiovascular risk. Although clinical trials are underway to document the safety and efficacy of this approach, Much is Still unknown about this endogenous system. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the periphery and regulate the central neural circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake, the stimulation of the CB, receptor with Delta(9)-tetrahydrocannabiol (Delta(9)-THC) enhances food consumption, while its blockade with receptor antagonists is an emerging relevant therapeutic means to reduce body weight. Rimonabant is the first of a new class of drugs that interferes with the endocannabinoid system by blocking the CB1 receptor. In recent clinical studies, a substantial reduction in body weight and waist circumference was associated with an improvement of the cardiovascular risk profile. In particular, increased HDL cholesterol, decreased serum triglycerides and improved insulin sensivity were observed. Further research will serve to establish the role of these compounds in cardiovascular risk management.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Journal or Publication Title: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
Publisher: JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
ISSN: 0947-7349
Date: February 2006
Volume: 114
Number: 2
Number of Pages: 7
Page Range: pp. 75-81
Identification Number: 10.1055/s-2006-923885
Publication Status: Published
URI: http://wrap.warwick.ac.uk/id/eprint/33703

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us